Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin with or without Cetuximab in Metastatic/Recurrent Head and Neck Cancer
NCT00003809Phase 3Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Aug 1999
- Primary completion
- Sep 2004
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in squamous cell carcinoma of the head and neck (HNSCC) comparing Cisplatin + Cetuximab with Cisplatin + Placebo (2 arms). Primary endpoints: Overall Survival, Objective Response Rate and 1 more. Started Aug 1999; status: completed.
02
Drugs
cetuximab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00003809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003809.